A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Phase of Trial: Phase II
Latest Information Update: 10 May 2014
At a glance
- Drugs MSDC 0602 (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2012 Positive topline data reported in a Metabolic Solutions Development Company media release.
- 03 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.